IP Library Granted Patent US 10,279,073
Granted Patent B2
US 10,279,073 · App. 14/055,712 · Granted May 7, 2019

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same

Inventors: Ronald Dieck (Palo Alto, CA); Ian J. Handley (Mountain View, CA); Neil Winterbottom (Mountain View, CA); Joanna Wong (Mountain View, CA)
Assignee: Baxter International Inc.
A61L24/108A61L24/043A61L24/10A61L31/041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,279,073
App. No.
14/055,712
Granted
May 7, 2019
Kind
B2
Abstract

Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits for use in preparing the subject compositions. The subject compositions, kits and systems find use in a variety of different applications.

Claims (12)

1. A phase invertible composition produced by combining:

(a) a liquid proteinaceous substrate comprising albumin, and

(b) a preformed liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid aldehyde crosslinking agent and a glycosaminoglycan, wherein at least a portion of the bound crosslinking agent molecules retain a free crosslinking aldehyde moiety that can bind proteins in the proteinaceous substrate, and

wherein said macromolecular crosslinking agent is a reaction product of heat stabilized glutaraldehyde and hyaluronic acid.

2. The phase invertible composition according to claim 1 , wherein said proteinaceous substrate further comprises a tackifying agent.

3. The phase invertible composition according to claim 1 , wherein said proteinaceous substrate further comprises a plasticizer.

4. The phase invertible composition according to claim 1 , wherein said proteinaceous substrate further comprises a carbohydrate.

5. A solid phase composition produced by a method of claim 1 .

6. A phase invertible composition produced by combining:

(a) a liquid proteinaceous substrate comprising albumin, and

(b) a preformed liquid crosslinking composition comprising a macromolecular crosslinking agent which comprises a reaction product of an excess of a liquid heat stabilized glutaraldehyde and hyaluronic acid,

wherein said phase invertible composition has an average burst of about 200 to about 850 mmHg, as measured at about room temperature.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045754/0904 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2016
From: TENAXIS MEDICAL, INC.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 040662/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2013
From: DIECK, RONALD; HANDLEY, IAN J.; WINTERBOTTOM, NEIL; WONG, JOANNA
To: TENAXIS MEDICAL, INC.
Reel/Frame 031426/0882 →
Continuity (4)
Continuation 13471746 · May 15, 2012
Continuation 12326835 · Dec 2, 2008
Provisional Application 60991867 · Dec 3, 2007
Related Publication 20140041547A1 · Feb 13, 2014